Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and molecular aspects

Current Pharmaceutical Design

Volumn 12, Issue 10, 2006, Pages 1173-1193

  Lenato, G M ^a   Guanti, G ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

ALK1; Angiogenesis; Endoglin; HHT; Rendu Osler Weber syndrome; SMAD; TGF

Indexed keywords

CYTOKINE; ENDOGLIN; PROTEIN SERINE THREONINE KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

AGE; ANEMIA; ANGIOGENESIS; ARTERIOVENOUS MALFORMATION; AUTOSOMAL DOMINANT DISORDER; CHROMOSOME 12Q; CHROMOSOME 9Q; CLINICAL FEATURE; EPISTAXIS; GENE MAPPING; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GREAT BLOOD VESSEL; HAPLOIDY; HUMAN; MICROANGIOPATHY; MOLECULAR GENETICS; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN FAMILY; PULMONARY HYPERTENSION; RARE DISEASE; RECURRENT DISEASE; RENDU OSLER WEBER DISEASE; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; STROKE; SYMPTOMATOLOGY; TELANGIECTASIA; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; GENETICS; GENOTYPE; PEDIGREE; PHENOTYPE;

ACTIVIN RECEPTORS, TYPE II; ANTIGENS, CD; GENOTYPE; HUMANS; MEMBRANE PROTEINS; PEDIGREE; PHENOTYPE; RECEPTORS, CELL SURFACE; SMAD PROTEINS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 33745008653     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361291     Document Type: Review

References (155)

1. Shovlin C, Letarte M. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-729.
2. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Int Med 1999; 245: 31-39.
3. Plauchu H, Bideau H. Epidemiologie et constitution d'un registre de population a propos d'une concentration geographique d'une maladie hereditaire rare. Population 1984; 4-5: 765-786.
4. Jessurun GA, Kamphuis DJ, van der Zande, FH Nossent JC Cerebral arteriovenous malformations in the Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arberiovenous malformations. Clin Neurol Neurosurg 1993; 95: 193-198.
5. Guttmacher AE, McKinnon WC, Upton MD. Hereditary hemorrhagic telangiectasia: a disorder in search of the genetics community. Am J Med Genet 1994; 52: 252-253.
6. Snyder LH, Doan CA. Clinical and experimental studies in human inheritance: is the homozygous form of multiple telangiectasia lethal? J Lab Clin Med 1944; 29: 1211-1216.
7. Muller J-Y, Michailov T, Izrael V, Bernard J. Maladie de Rendu-Osler dans une grande famille saharienne. La Nouvelle Presse Med 1978; 7: 1723-1725.
8. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectesia (Redu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67.
9. Plauchu H, de Chadarévian J-P, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297.
10. Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet 1992; 29: 527-530.
11. Morgan T, McDonald J, Anderson C, Ismail M, Miller F, Mao R, et al. Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). Pediatrics 2002; 109: E12.
12. Cymerman U, Vera S, Karabegovic A, Abdalla S, Litarte M. Characterisation of 17 novel endoglin mutations associated with hereditary hemorrhagic telangiectasia. Hum Mutat 2003; 21: 482-92.
13. McDonald MT, Papenberg KA, Ghosh S, Glatfelter AA, Biesecker BB, Helmbold EA, et al. A diseaselocus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nature Genet 1994; 6: 197-204.
14. Shovlin CL, Hughes JMB, Tuddenham EGD, Temperley I, Perembelon YFN, Scott J, et al. A gene fbr hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nature Genet 1994; 6: 205-209.
15. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-β binding protein of endothelial cells is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994 8: 345-351.
16. Fernandez-Ruiz E, St-Jaques S, Bellon T, Letarte M, Bernabeu C. Assignment of the human endoglin gene (END) to 9q34>qter. Cytogen Cell Genet 1993; 64: 204-207.
17. Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukaemic cell line. J Immunol 1988; 141: 1925-1933.
18. Gougos A, Letarte M Biochemical characterisation of the 44G4 antigen from the HOON pre-B leukaemic cell line. J Immunnol 1988; 141: 1934-1940.
19. Letarte M, Greaves A, Vera S. CD105 (endoglin) cluster report. In: Schlossman SF, Boumsell L, Gilks W, Harlan J, Kishimoto T, Morimoto C, et al. Leukocyte Typing V. White Cell Differentiation Antigens 1995 Oxford University Press, Oxford, pp 1756-9.
20. Bühring HJ, Müller CA, Letarte M, Gougos A, Saalmüller A, van Agthoven A J, et al. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 1991; 5: 841-847.
21. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 1995; 1: 4456-65.
22. St Jacques S, Cymerman U, Pece N, Letarte M. Molecular characterisation and in situ localisation of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells Endocrinology 1994; 134: 2645-2657.
23. Gougos A. St Jacques S, Greaves A, O'Connell PJ, d'Apice AJ, Buhring HJ, et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukaemic cells, and syncytiotrophoblasts. Int Immunol 1992, 4: 83-92.
24. Chen CZ, Li M, de Graaf D, Monti S, Gottgens B, Sanchez MJ, et al. Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stemcells. Proc Natl Acad Sci USA 2002; 99: 15468-73.
25. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, et al. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1-7.
26. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000; Dec 153(2): 323-35.
27. Li C, Guo B, Bernabéu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech 2001; 15: 437-49.
28. Pece-Barbara N, Cymerman U, Vera S, Marchuk, DA, Letarte M. Expression analysis of four endoglin missense mutations suggests haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 1999; 8: 2171-2181.
29. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992; 22: 393-397.
30. Moren A, Ichijo H, Miyazono K. Molecular cloning and characterisation of the human and porcine transforming growth factor-beta type III receptors. Biochem Biophys Res Commun 1992; 30: 356-62.
31. Wang X-F, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA Expression cloning and characterisation of the TGF-β type III receptor. Cell 1991; 67: 797-805.
32. López-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor. Cell 1991; 67: 785-795.
33. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992, 267: 19027-19030.
34. Yamashita H, Ichijo H, Grimsby S, Morén A, ten Dijke P and Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β. J Biol Chem 1994; 269: 1995-2001.
35. Madri JA, Bell L, Merwin JR. Modulation of vascular cell behavior by transforming growth factors beta. Mol Reprod Dev 1992; 32: 121-6.
36. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, et al. Endoglin modulates cellular responses to TGF-β1. J Cell Biol; 1996 133: 1109-1121.
37. Barbara NP, Wrana JL and Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274: 584-594.
38. McAllister KA, Baldwin MA, Thukkani AK, Gallione CJ, Berg JN, Porteous ME, et al. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum Mol Genet 1995; 4: 1983-1985.
39. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990; 265: 8361-8364.
40. Lux A, Gallione CJ, Marchuk DA. Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms. Hum Mol Genet 2000: 9: 745-755.
41. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, et al. Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993; 23: 2340-2345.
42. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002 9; 277: 29197-209.
43. Shovlin C L, Hughes JM, Scott J, Seidman CE, Seidman J G. Characterisation of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 1997; 61: 68-79.
44. Gallione C J, Klaus D J, Yeh E Y, Stensel T T, Xue Y, Anthony K, et al. Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles. Hum Mutat 1998; 11: 286-294.
45. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999; 8: 1893-900.
46. Pece N, Vera S, Cymerman U, White Jr RI, Wrana J L, Letarte M. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant-negative. J Clin Invest 1997; 100: 2568-2579.
47. Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA, Letarte M. Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 1997; 50: 265-276.
48. Raab U, Velasco B, Lastres P, Letamendia A, Cales C, Langa C, et al. Expression of normal and truncated forms of human endoglin. Biochem J 1999; 339: 579-588.
49. Paquet ME, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C, Letarte M Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 2001 Jun 15; 10(13): 1347-57.
50. Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE, et al. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000; 156: 911-923.
51. Heutink P, Haitjema T, Breedveld GJ, Janssen B, Sandkuijl LA, Bontekoe CJM, et al. Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J Med Genet 1994; 31: 933-936.
52. McAllister KA, Lennon F, Bowles-Biesecker B, McKinnon WC, Helmbold EA, Markel DS, et al. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J Med Genet 1994, 31: 927-932.
53. Porteous ME, Curtis A, Williams O, Marchuk D, Bhattacharya SS, Burn J. Genetic heterogeneity in hereditary haemorrhagic telangiectasia. J Med Genet 1994 Dec; 31: 925-6.
54. Berg JN, Guttmacher AE, Marchuk DA, Porteous ME Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? J Med Genet 1996; 33: 256-257.
55. Berg J, Porteous M, Reinhardt D, Gallione C, Holloway S, Umasunthar T, et al. Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations. J Med Genet 2003, 40: 585-90.
56. Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA, et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995; 5: 21-28.
57. Vincent P, Plauchu H, Hazan J, Faure S, Weissenbach J, Godet J. A third locus for hereditary haemorrhagic telangiectasia maps to chromosome 12q. Hum Mol Genet 1995; 4: 945-949.
58. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marrondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nature Genet 1996; 13: 189-195.
59. Kucherlapati R, Craig I, Marynen P. Report and abstracts of the Second International Workshop on Human Chromosome 12. Cytogenet Cell Genet 1994; 67: 245-76.
60. Attisano L, Cárcamo J, Ventura F, Weis FMB, Massagué J, Wrana J L Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993; 75: 671-680.
61. ten Dijke P, Ichijo H, Fransen P, Schulz P, Saras J, Toyoshima H, et al. Activin receptor-like kinases: a novel subclass of cell surface receptors with predicted serine/threonine kinase activity. Oncogene 1993; 8: 2879-2887.
62. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42-52.
63. Berg JN, Gallione CJ, Stensel TT, Johnson DW, Allen WP, Schwartz CE, et al. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 1997; 61: 60-67.
64. Abdalla SA, Cymerman U, Johnson RM, Deber CM, Letarte M. Disease-associated mutations in conserved residues of ALK-1 kinase domain. Eur J Hum Genet 2003, 11: 279-87.
65. ten Dijke P, Yamashita H, Ichijo H, Fransen P, Laiho M, Miyazono K, Heldin C-H. Characterisation of the type I receptors for transforming growth factor-β receptor like and activin. Science 1994; 264: 101-104.
66. Massagué J, Attisano L and Wrana J L. The TGF-β family and its composite receptors. Trends Cell Biol 1994; 4: 172-178.
67. Miyazono, K, ten Dijke P, Ichijo H and Heldin C-H. Receptors for transforming growth factor-β. Adv Immunol 1994; 55: 181-220.
68. Wrana J L, Attisano L, Cárcamo J, Sentella A, Doody J, Laiho M, et al. TGF-β signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-1014.
69. Georgi LL, Albert PS, Riddle DL. daf-1, a C. elegans gene controlling dauer larva development, encodes a novel receptor protein kinase. Cell 1990; 18: 635-45.
70. Mathews LS, Vale WW. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991; 14: 973-82.
71. Attisano L, Wrana JL, Cheifetz S, Massague J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992; 1068: 97-108.
72. Fransen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH, Miyazono K. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 1993; 19: 681-92.
73. Matsuzaki K, Xu J, Wang F, McKeehan WL, Krummen L, Kan M. A widely expressed transmembrane serine/threonine kinase that does not bind activin, inhibin, transforming growth factor beta, or bone morphogenic factor. J Biol Chem 1993; 15: 12719-23.
74. Kang Y, Reddi AH. Identification and cloning of a novel type I serine/ threonine kinase receptor of the TGF-beta/BMP superfamily in rat prostate. Biochem Mol Biol Int 1996; 40: 993-1001.
75. Ryden M, Imamura T, Jornvall H, Belluardo N, Neveu I, Trupp M, et al. A novel type I receptor serine-threonine kinase predominantly expressed in the adult centralnervous system. J Biol Chem 1996; 29271: 30603-9.
76. Tsuchida K, Mathews LS, Vale WW. Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor. Proc Natl Acad Sci USA 1993; 1: 11242-.
77. Garamssegi N, Dore JJ Jr, Penheiter SG, Edens M, Yao D, Leof EB. Transforming growth factor beta receptor signaling and endocytosis are linked through a COOH terminal activation motif in the type I receptor. Mol Biol Cell 2001; 12: 2881-93.
78. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanisms of activation of the TGF-β receptor. Nature 1994; 370: 341-347.
79. Attisano L, Wrana JL, Montalvo E, Massagué J. Activation of signaling by the activin receptor complex. Mol Cell Biol 1996; 16: 1066-1073.
80. Miyazono K, Ten Dijke P, Heldin CH. TGF-beta signaling by Smad proteins. Adv Immunol 2000; 75: 115-57.
81. Carcamo J, Weis FMB, Ventura F, Wieser R, Wrana JL, Attisano L and Massagué J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol 1994, 14: 3810-3821.
82. Muramatsu M, Yan J, Eto K, Tomoda T, Yamada R, Arai K. A chimeric serine/ threonine kinase receptor system reveals the potential of multiple type II receptors to cooperate with transforming growth factor-beta type I receptor. Mol Biol Cell 1997; 8: 469-80.
83. Anders RA, Leof EB. Chimeric granulocyte/macrophage colony-stimulating factor/transforming growth factor-beta (TGF-beta) receptors define a model system for investigating the role of homomeric and heteromeric receptors in TGF-beta signaling. J Biol Chem 1996; 271: 21758-66.
84. Persson U, Souchelnytskyi S, Fransen P, Miyazono K, ten Dijke P, Heldin CH. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor. J Biol Chem 1997; 272: 21187-94.
85. Vivien D, Attisano L, Wrana JL, Massague J. Signaling activity of homologous and heterologous transforming growth factor-beta receptor kinase complexes. J Biol Chem 1995; 270: 7134-41.
86. Luo K, Lodish HF. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerisation of the cytoplasmic domain of the type I TGF-beta receptor and eterodimerisation with the type II receptor are both required for intracellular signal transduction. EMBO J 1996; 2: 4485-96.
87. Lux A, Attisono L, Marchuk DA. Assignment of transforming growth factor β1 and β3 and a third new ligand to the type I receptor ALK-1. J Biol Chem 1999; 274: 9984-9992.
88. Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M. Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet 2000; 1: 1227-37.
89. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003; 40: 865-71.
90. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 2: 325-34.
91. Cymerman U, Vera S, Pece-Barbara N, Bourdeau A, White RJ, Dunn J, et al. Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin. Pediatr Res 2000; 47: 24-35.
92. Lastella P, Sabba C, Lenato GM, Resta N, Lattanzi W, Gallitelli M, et al. Endoglin gene mutations and polymorphisms in Italian patients with hereditary haemorrhagic telangiectasia. Clin Genet 2003; 63: 536-40.
93. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
94. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-91.
95. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 13: 685-700.
96. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 1: 3091-100.
97. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611-7.
98. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000; 12: 235-43.
99. Iavarone A, Massague J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997; 22: 417-22.
100. Shimizu A, Kato M, Nakao A, Imamura T, ten Dijke P, Heldin CH, et al. Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. Genes Cells 1998; 3: 125-34.
101. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 1998; 25: 786-90.
102. Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ. Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell 1998; 20: 797-808.
103. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Misel DE, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999; 1: 260-6.
104. Macías-Silva, M, Hoodless PA, Jun Tang S, Buchwald M, Wrana JL. Specific activation of Smad1 signalling pathways by the BMP7 type I receptor ALK2. J Biol Chem 1998; 273: 25628-25636.
105. Feng XH, Derynck R. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. EMBO J 1997; 1: 3912-23.
106. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000; 14: 2626-31.
107. Chen YG, Massague J. Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J Biol Chem 1999; 5: 3672-7.
108. Gajdusek CM, Luo Z, Mayberg MR. Basic fibroblast growth factor and transforming growth factor beta-1: synergistic mediators of angiogenesis in vitro. J Cell Physiol 1993; 157: 133-44.
109. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993; 204: 356-63.
110. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8: 21-43.
111. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000; 50: 1-15.
112. Fielmeden DC, Blann AD, Lip GY. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003; 24: 586-603.
113. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
114. Roelen BA, van Rooijen MA, Mummery CL. Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn 1997; 209: 418-30.
115. Jonker L, Arthur HM. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev 2002; 110:193-6.
116. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 28: 1534-7.
117. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 104: 1343-51.
118. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, et al. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000, 1: 42-53.
119. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1 Nat Genet 2000; 26: 328-31.
120. Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialisation and vascular remodeling. Circ Res 2003, 3: 682-9.
121. Sorensen LK, Brooke BS, Li DY, Urness LD. Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev Biol 2003, 1: 235-50.
122. Cumano A, Dieterlen-Lievre F, Godin I. Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 1996; 20: 907-16.
123. Stehbens WE. Structural and architectural changes during arterial development and the role of hemodynamics. Acta Anat (Basel) 1996; 157: 261-74.
124. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999; 4: 403-14.
125. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 29: 741-53.
126. Roman BL, Pham VN, Lawson ND, Kulik M, Childs S, Lekven AC, et al. Disruption of acvr11 increases endothelial cell number in sebrafish cranial vessels. Development 2002; 129: 3009-19.
127. Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M. Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 2001; 158: 2011-20.
128. Bourdeau A, Faughnan ME, Letarte M. Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2000; 10: 279-85.
129. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003, 1: 473-82.
130. van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res 2003; 1: 20-31.
131. Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002; 15: 4495-501.
132. Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, et al. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol 2002; 193: 299-318:
133. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 2: 1743-53.
134. Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 203; 13: 301-7.
135. Olivieri C, Mira E, Delu G, Pagella F, Zambelli A, Malvezzi L, et al. Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia. J Med Genet 2002; 39: E39.
136. McDonald JE, Miller FJ, Hallam SE, Nelson L, Marchuk DA, Ward KJ. Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 2000; 14: 320-7.
137. Abdalla SA, Geisthoff UW, Bonneau D, Plauchu H, McDonald J, Kennedy S, et al. Visceral manifestations in hereditary haemorrhagic telangiectasia type 2. J Med Genet 2003; 40: 494-502.
138. Wallace GM, Shovlin CL. A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax 2000; 55: 685-90.
139. Gallione CJ, Scheessele EA, Reinhardt D, Duits AJ, Berg JN, Westermann CJJ, et al. Two common endoglin mutations in families with hereditary hemorrhagic telangiectasia in the Netherlands Antilles: evidence for a founder effect. Hum. Genet 2000; 40-44.
140. Lesca G, Plauchu H, Coulet F, Lefebvre S, Plessis G, Odent S, et al. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat 2004; 23: 289-99.
141. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 1998; 4: 805-14. Erratum in: J Cell Biol 1998; 1: 1287.
142. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 15: 43799-808.
143. Botella LM, Sanchez-Elsner T, Rius C, Corbi A, Bernabeu C. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem 2001; 14: 34486-94.
144. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003; 1: 2677-85.
145. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 13: 295-309.
146. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000; 11: 23-35.
147. Yamaguchi H, Azuma H, Shigekiyo T, Inoue H. A novel missense mutation in the endoglin gene in hereditary hemorrhagic telangiectasia. Thromb Haemost 1997; 77: 243-247.
148. Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe M, et al Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19: 140-8.
149. Klaus DJ, Gallione CJ, Antony K, Yeh EY, Yu J, Lux A, et al. Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Hum. Mutat 1998, Online Mutations in Brief, No. 164.
150. Kjeldsen AD, Brusgaard K, Poulsen L, Kruse T, Rasmussen K, Green A, Vase P. Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families. Am J Med Genet 2001; 1: 298-302.
151. Lin WD, Wu JY, Hsu HB, Tsai FJ, Lee CC, Tsai CH. Mutation analysis of a family with hereditary hemorrhagic telangiectasia associated with hepatic arteriovenous malformation. J Formos Med Assoc 2001; 100: 817-9.
152. D'Abronzo FH, Swearingen B, Klibanski A, Alexander JM. Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumours. J Clin Endocrinol Metab 1999; 84: 1716-21.
153. Gomis-Ruth FX, Sola M, de la Cruz F, Coll M. Coupling factors in macromolecular type-IV secretion machineries. Curr Pharm Des 2004; 10(13): 1551-65.
154. Hool LC. Protein kinase C isozyme selective peptides - a current view of what they tell us about location and function of isozymes in the heart. Curr Pharm Des 2005; 11(4): 549-59.
155. Petersen P. Ximelagatran - a promising new drug in thromboembolic disorders. Curr Pharm Des 2005, 11(4): 527-38.